PharmaTalkRadio

At the inaugural Patients as Partners Europe event, Duncan Arbour from inVentiv Health explores the ‘how’ and ‘when’ for involving patients within clinical and commercial to enhance the development and delivery of innovative therapies.  The patient voice as a strategic driver is being included much earlier in the development process than ever before. In this session, pharmaceutical, biotech and de...

Alastair Kent, Director of the Genetic Alliance UK, talks about how patients can and are influencing policy within the EU.  The Patients as Partners Europe program seeks to understand and incorporate the patient's voice in designing clinical trials and developing a clinical endpoint, as well as vastly improve the patient's entire experience in a clinical trial. The 2nd annual Patients as Partners...

Originally presented during the business aspects plenary session at Immuno-Oncology 360° 2017, Dr Axel Hoos of GSK discusses business models for complex science.  Save the date for the 4th annual IO360° conference, taking place February 7-9, 2018 in New York City. Dr Hoos returns as lead advisor, as well as moderating a talk called, "Investor Roundtable: The Role of IO within Large Pharma - Where...

Chief Medical Officer at nanoString Technologies, Dr Alessandra Cesano, brings to light the increasingly critical role of predictive biomarkers in cancer immunotherapy, originally presented during the translational science and new technologies session from 2017’s Immuno-Oncology 360° conference. Save the date for the 4th annual IO360° conference, taking place February 7-9, 2018 in New York City. A...

Originally recorded during the 3rd annual Immuno-Oncology 360° in February 2017, this panel discussion addresses clinical challenges within immuno-oncology. One of the IO360° lead advisors, Dr James Gulley of the National Cancer Institute, moderates the session between Merck’s Dr Roy Baynes, nanoString Technologies’ Dr Alessandra Cesano, MD Anderson’s Dr Patrick Hwu, and inVentiv Health’s Robert M...

Originally recorded at the inaugural Patients as Partners Europe event, held in London in February 2017. Patient, industry, and regulatory perspectives are provided by Alastair Kent of Genetic Alliance UK, Dr Anton Hoos of Amgen Europe, and Isabelle Moulon of the EMD as they discuss on innovative ways of to include patient involvement in medicines development. The Patients as Partners Europe progr...

Originally recorded during a panel session at the 2017's Immuno-Oncology 360°, Mark Simon of Torreya Partners moderates the conversation around issues, controversies, and other important business aspects of IO. He's joined by IO360° lead advisor and SVP at GSK, Dr Axel Hoos, Dr Robert Ang of Neon Therapeutics, Dr Jeffrey Bockman from Defined Health, Dr Jeffrey Legos from Novartis Pharmaceuticals,...

During the preclinical science plenary session from 2017's Immuno-Oncology 360° conference, Dr Charles Drake's talks about "Sequencing of Combination Agents."  Dr Drake is Director, Genitourinary Oncology and Co-Director Immunotherapy Associate Director, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center. Previously, he was an associate professor of oncology, urology...

At 2016's Rational Combinations 360° meeting, Dr Patrick Hwu of MD Anderson Cancer Center delivered a keynote address on the future outlook behind combination immunotherapy. Dr Hwu addresses innovations behind combination therapy, specifically focusing on what’s next after checkpoint combinations and whether combination of adoptive T-cell therapy and anti-checkpoint inhibitor therapies are the nex...

The 3rd annual DPharm Europe: Disruptive Innovations to Advance Clinical Trials event is led by Co-Chairs Dr Sue Collier (GSK) and Dr Jeff Kasher (Patients Can’t Wait).  This radio blogcast gives a five minute overview of the event, which presents global case studies on: Real World Clinical Trial Strategies and ResultsNew Leadership in Driving Clinical Trial InnovationStrategies to Validate the Si...

We are delighted to bring the Patients as Partners US event to Europe on February 6-7 in London. We would like to thank our European attendees at the US conference for challenging and encouraging us to bring the conference to Europe. The goal of creating patient centricity as the ecosystem within pharma can not be achieved without patient involvement.  Patients as Partners Europe is accredited by...

 The 3rd annual Immuno-Oncology 360° event takes place February 1-3, 2017 in NYC.  Lead advisors, Dr Axel Hoos (GSK) and Dr James Gulley (NCI) co-present a program that provides a  360-degree approach addressing the most-up-to-date information regarding business aspects, clinical advancements and scientific data that will help accelerate clinical trials and FDA approval, ultimately transforming th...

Members of the DPharm team engage in an informal conversation to highlight what's happening in innovation and the latest thinking to disrupt clinical trials at the 6th annual event. Also discussed is a brief history of how this conference dedicated to applying disruptive thinking to clinical trials came to be. This conversation is well worth listening to if you plan to attend DPharm or want to get...

Pfizer’s “Blue Sky” approach to transforming clinical research in Parkinson’s disease is an inspiring example of patient-centric innovation. Conference Forum's, Valerie Bowling welcomes co-host, Ed Miseta, Clinical Leader.com in a discussion with members of Pfizer’s "Blue Sky" team. Together they discuss the vision, goals and journey in taking a new approach to advancing drug development. More spe...

This discussion provides helpful approaches for Chief Medical Officers (CMOs) and other R&D leadership in biotech on how to communicate effectively in times of good, bad or unexpected news. Also discussed in this program are factors to evaluate for the discontinuation of a program. Dr Mark Weinberg, Chief Medical Officer and Managing Director of Halloran Consulting Group will be joined by Dr L...

What is the quality, capacity and efficiency of running clinical trials in Puerto Rico? In this discussion we speak with Dr Myrto Lee, Director, PwC'sStrategy&, UK and Dr Kosmas Kretsos, Executive Director of the Puerto Rico Consortium for Clinical Investigation to learn about key initiatives and outcomes so far to make running clinical trials more attractive in Puerto Rico. For more informati...

Frustrated that a promising therapy for a rare cancer was sitting in a freezer due to the lack of a relatively modest amount of funding, author Alexander Masters helped lead a campaign to crowd-fund a clinical trial: the result, iCancer.org.uk. The money required was indeed raised by a wealthy individual primarily, in return for being in the trial. At DPharm Europe, Pfizer's Craig Lipset interview...

Generic drugs can be repurposed to create effective treatments in unsolved diseases. However, there is no economic incentive for industry to pay for a clinical validation and regulatory approval process for most generic drug repurposing because it will not achieve the necessary ROI. Cures Within Reach, FindaCure, Numbers For Good and the National Health Service in England are working together to t...

Pharmatalk's Valerie Bowling welcomes Anton (Tony)  Hoos, MD, PhD, Head of Medical, Amgen Europe and Marc Boutin, JD, Chief Executive Officer, National Health Council.  We address how industry and patients can work together to incorporate the patient voice in drug development and to improve patient's experience in clinical trials. We examine the current challenges and barriers to patient involveme...

PharmaTalk Radio's Valerie Bowling welcomes Immuno-Oncology 360° Co-Chair James Gulley, MD, PhD,National Cancer Institute as he leads a discussion with fellow Co-Chair, Axel Hoos, MD, PhD, GlaxoSmithKline. Together they discuss what's currently happening in Immuno-Oncology and its impact on how cancer is being treated. They cover the latest challenges and next steps. More specifically they also ad...

At Dpharm US 2015, Katherine Vandebelt, Global Head, Clinical Innovation, Eli Lilly hosted a talk show on MakingClinical Trials a Care Option for Patients to fantastic reviews. Valerie Bowling, producer welcomes Katherine as she hosts a similar session on Pharma Talk Radio. About the Show: This talk demonstrates how an organized multispecialty healthcare system, clinical research site network and...

In this episode of Pharma Talk Radio, we feature medical oncologist, Dr Anna Pavlick, Director of the Melanoma Program at the NYU Cancer Institute on Safety Elements of Cancer Immunotherapies. Dr Pavlick originally gave this presentation in June 2015 at the IO360 conference.  Her talk focuses on immune related adverse affects of immuno therapy. More specifically, she covers: •    Identifying warni...

At the May 2015 Chief Medical Officer’s Summit in Boston, we featured a session on: How the Availability of Capital Impacts the Role of the CMO In this session, the panelists cover: Optimal use of the proceeds Determining a development path, new molecules vs. new studies on the same molecules Appropriate stewardship of the capital Balancing short-term and long-term objectives; particularly when th...

At the May 2015 Chief Medical Officer's Summit in Boston, we featured a session on: How Investors Assess R&D Biotech Management Take a look at the details below: In this session, we begin with a presentation on a perspective on the method of evaluating a disease space, which includes a comprehensive understanding of 1) the science, 2) the competitive landscape and 3) the management teams for e...

At the Conference Forum's 2015 Chief Medical Officer's Summit in Boston, David Schenkein, MD, CEO, Agios provided a warm and personal keynote sharing his journey as a Physican CEO. In this recording of the session, gain an insight into Dr Schenkein's views on leadership in running a biotech company and more specifically: The journeyThe people and mentorshipsPrioritizing resourcesSuccesses and fail...